Table 3 Hazard ratios for relapse-free survival and overall survival in cervical cancer.
Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
Relapse-free survival | ||||
Age (≥ 45/ < 45) | 0.94 (0.44–2.03) | 0.88 | ||
Histology (non-Scc/Scc) | 1.86 (0.86–4.02) | 0.12 | 1.84 (0.84–4.01) | 0.13** |
Size (≥ 4 cm/ < 4 cm) | 1.38 (0.55–3.43) | 0.49 | ||
Parametrium involvement (positive/negative) | 2.00 (0.76–5.32) | 0.16 | 2.45 (0.92–6.56) | 0.07** |
Pelvic lymph node metastasis (positive/negative) | 5.25 (1.57–17.5) | 0.007* | 5.64 (1.68–18.9) | 0.005** |
Concurrent use of systemic agent (CCRT/RT) | 0.14 (0.02–1.05) | 0.05 | 0.17 (0.02–1.25) | 0.08** |
PIK3CA alterations (positive/negative) | 1.08 (0.47–2.52) | 0.85 | ||
STK11 alterations (positive/negative) | 1.77e−9 (–) | 0.99 | ||
PTEN alterations (positive/negative) | 1.09 (0.37–3.21) | 0.88 | ||
HPV infection (positive/negative) | 0.83 (0.25–2.77) | 0.76 | ||
HPV 16 or 18 (HPV 16/18/non-HPV 16/18) | 1.58 (0.58–4.34) | 0.37 | ||
Overall survival | ||||
Age (≥ 45/ < 45) | 1.63 (0.48–5.59) | 0.43 | ||
Histology (non-Scc/Scc) | 1.08 (0.32–3.69) | 0.90 | ||
Size (≥ 4 cm/ < 4 cm) | 1.82 (0.39–8.44) | 0.44 | ||
Parametrium involvement (positive/negative) | 1.22 (0.32–4.61) | 0.77 | ||
Pelvic lymph node metastasis (positive/negative) | 6.51 (0.82–50.1) | 0.08 | ||
Concurrent use of systemic agent (CCRT/RT) | 1.40e−9 (–) | 0.99 | ||
PIK3CA alterations (positive/negative) | 1.35 (0.39–4.63) | 0.63 | ||
STK11 alterations (positive/negative) | 4.98e−9 (–) | 0.99 | ||
PTEN alterations (positive/negative) | 0.73 (0.09–5.67) | 0.76 | ||
HPV infection (positive/negative) | 1.24 (0.16–9.70) | 0.84 | ||
HPV 16 or 18 (HPV 16/18/non-HPV 16/18) | 3.66 (0.46–28.9) | 0.22 | ||
